# Effects of Dapagliflozin and Metformin on Vascular Function in Newly-Diagnosed Treatment-Naive Type 2 Diabetes

> **NCT05440591** · PHASE4 · UNKNOWN · sponsor: **Tan Tock Seng Hospital** · enrollment: 150 (estimated)

## Conditions studied

- Diabetes

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** MetFORMIN 500 Mg Oral Tablet
- **DRUG:** Dapagliflozin / metFORMIN Pill

## Key facts

- **NCT ID:** NCT05440591
- **Lead sponsor:** Tan Tock Seng Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04-01
- **Primary completion:** 2023-05-10
- **Final completion:** 2023-05-10
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2022-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05440591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05440591, "Effects of Dapagliflozin and Metformin on Vascular Function in Newly-Diagnosed Treatment-Naive Type 2 Diabetes". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05440591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*